GGrantIndex
Sort

23,748 grants matching melanoma

Dendritics Cell Immunotherapy for Colorectal Cancer

$288,476
Lawrence Fong · University Of California, San Francisco · R01 · FY2007 · CA

Enhancing antitumor immunity with anti-PD-1 antibody in follicular lymphoma.

$288,425
Sattva S Neelapu · University Of Tx Md Anderson Can Ctr · R21 · FY2010 · CA

Project 1: Targeted sequencing and clinicopathology to evaluate primary melanoma molecular subtypes and outcomes

$288,413
Marianne Berwick · University Of New Mexico Health Scis Ctr · P01 · FY2019 · CA

Generation of Anti-Melanoma T Cells Derived from Human Embryonic Stem Cells

$288,409
Jerome A. Zack · California Institute Of Technology · P01 · FY2013 · CA

Gene Discovery in Melanoma Etiology

$288,392
Timothy R Rebbeck · Wistar Institute · P50 · FY2008 · CA

Validation of genomic targets in melanoma

$288,354
Mohammed Kashani-Sabet · University Of California, San Francisco · R01 · FY2008 · CA

Mimimal-Perturbation Dynamic Control of the Melanoma Gene Regulatory Network

$288,350
Dan Schonfeld · University Of Illinois At Chicago · R01 · FY2011 · GM

MECHANISMS OF ALCOHOL RELATED INHIBITION OF NK ACTIVITY

$288,332
Washington State University · R01 · FY2002 · AA

Personal tumor neoantigens for immunity against chronic lymphocytic leukemia

$288,332
Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · R01 · FY2014 · CA

Manipulation of Tumor Specific Immunity

$288,325
Hans Schreiber · University Of Chicago · R01 · FY2016 · CA

Manipulation of Tumor Specific Immunity

$288,325
Hans Schreiber · University Of Chicago · R01 · FY2018 · CA

Manipulation of Tumor Specific Immunity

$288,325
Hans Schreiber · University Of Chicago · R01 · FY2017 · CA

Project 4

$288,300
Eva Hernando · New York University School Of Medicine · P50 · FY2020 · CA

Combination immunotherapies for the treatment of melanoma

$288,300
Michael W Fanger · Celdara Medical, Llc · R43 · FY2013 · CA

optimized Human Apyrase for Bone Cancer Pain Treatment

$288,298
Ridong Chen · Apt Therapeutics, Inc. · R43 · FY2013 · CA

Artificial Immune Moduating (AIM??)Platform for the Treatment of Cancer

$288,268
Bruce J McCreedy · Neximmune, Inc. · R43 · FY2013 · CA

High-Grade Astrocytoma-Specific Molecular Targeting

$288,259
Waldemar Debinski · Wake Forest University Health Sciences · R01 · FY2019 · CA

PRETARGETING STRATEGIES FOR CENTRAL NERVOUS MALIGNANCY RADIOIMMUNOTHERAPY

$288,255
Duke University · P50 · FY2001 · NS

PRETARGETING STRATEGIES FOR CENTRAL NERVOUS MALIGNANCY RADIOIMMUNOTHERAPY

$288,255
Duke University · P50 · FY2000 · NS

Regulation of RANKL Expression in T-Lymphocytes

$288,212
Yufang Shi · Univ Of Med/Dent Nj-R W Johnson Med Sch · P01 · FY2008 · AI

Role of DeltaNp63alpha in Vitamin D Mediated Cell Survival in Skin Cancer

$288,184
Madhavi P Kadakia · Wright State University · R01 · FY2012 · CA

Mechanism and Inhibition of Collagenolytic Activity

$288,155
Gregg B Fields · University Of Texas Hlth Science Center · R01 · FY2010 · CA

Novel Immuno-oncology Strategy for Targeted Cytotoxic Lymphocyte Activation

$288,105
Alexander Sasha Krupnick · Courier Therapeutics, Inc. · R41 · FY2018 · CA

Roles of Glycoconjugates and Redox Signaling in Tumor Biology

$288,086
David D Roberts · Division Of Clinical Sciences - Nci · Z01 · FY2008 · CA

Role of Immune Regulatory Pathways in BRAF targeted therapy In melanoma

$288,077
Arlene H Sharpe · University Of Tx Md Anderson Can Ctr · U54 · FY2014 · CA